Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Targovax ASA ( (GB:0RIS) ) just unveiled an update.
Circio Holding ASA has announced that its shares will trade ex-rights from 8 April 2026, meaning investors buying the stock from that date will not be eligible to participate in a planned subsequent offering of up to 7,638,888 new shares. The move clarifies the cut-off for rights participation and marks a step in the company’s ongoing capital-raising plans, which could support further development and commercialization of its circular RNA technology platform and strengthen its position in the advanced gene and cell therapy market.
The subsequent offering structure may impact existing shareholders’ dilution and trading dynamics around the ex-date, as investors adjust positions based on eligibility for the new shares. For Circio, the potential capital injection could provide additional resources to advance its circVec R&D programs in Stockholm, underpinning its strategy to establish its circular RNA expression system as a potential new standard in gene expression technologies.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing novel circular RNA expression technology for gene and cell therapies. Through its proprietary circVec platform, developed by its subsidiary Circio AB in Stockholm, the company aims to deliver next-generation RNA, DNA and viral therapeutics with significantly improved RNA stability and protein expression for applications in genetic medicine, cell therapy and chronic diseases.
Average Trading Volume: 10,110,733
Current Market Cap: NOK2.09B
See more insights into 0RIS stock on TipRanks’ Stock Analysis page.